NCT06115993View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

December 3, 2024

Study Completion Date

January 31, 2026

Conditions

Hepatitis B, Chronic

Interventions

DRUG

AHB-137 injection

AHB-137 injection will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Trial Locations (3)

Unknown

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Nanfang Hospital, Southern Medical University, Guangzhou

The First Hospital of Jilin University, Jilin

All Listed Sponsors

lead

Ausper Biopharma Co., Ltd.

INDUSTRY

NCT06115993 - A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients | Biotech Hunter | Biotech Hunter